Identification of genes related to heart failure using global gene expression profiling of human failing myocardium.

Although various management methods have been developed for heart failure, it is necessary to investigate the diagnostic or therapeutic targets of heart failure. Accordingly, we have developed different approaches for managing heart failure by using conventional microarray analyses. We analyzed gene expression profiles of myocardial samples from 12 patients with heart failure and constructed datasets of heart failure-associated genes using clinical parameters such as pulmonary artery pressure (PAP) and ejection fraction (EF). From these 12 genes, we selected four genes with high expression levels in the heart, and examined their novelty by performing a literature-based search. In addition, we included four G-protein-coupled receptor (GPCR)-encoding genes, three enzyme-encoding genes, and one ion-channel protein-encoding gene to identify a drug target for heart failure using in silico microarray database. After the in vitro functional screening using adenovirus transfections of 12 genes into rat cardiomyocytes, we generated gene-targeting mice of five candidate genes, namely, MYLK3, GPR37L1, GPR35, MMP23, and NBC1. The results revealed that systolic blood pressure differed significantly between GPR35-KO and GPR35-WT mice as well as between GPR37L1-Tg and GPR37L1-KO mice. Further, the heart weight/body weight ratio between MYLK3-Tg and MYLK3-WT mice and between GPR37L1-Tg and GPR37L1-KO mice differed significantly. Hence, microarray analysis combined with clinical parameters can be an effective method to identify novel therapeutic targets for the prevention or management of heart failure.

[1]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[2]  W. Koch,et al.  Differential gene expression and genomic patient stratification following left ventricular assist device support. , 2003, Journal of the American College of Cardiology.

[3]  J. Reagan,et al.  Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35* , 2006, Journal of Biological Chemistry.

[4]  K. Kawakami,et al.  A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. , 2007, The Journal of clinical investigation.

[5]  Hiroshi Asanuma,et al.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.

[6]  K. Shinjo,et al.  5-Nitro-2-(3-Phenylpropylamino)benzoic Acid Is a GPR35 Agonist , 2008, Pharmacology.

[7]  M. Asakura,et al.  Global gene expression profiling in the failing myocardium. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[8]  J. Rysä,et al.  Distinct Upregulation of Extracellular Matrix Genes in Transition From Hypertrophy to Hypertensive Heart Failure , 2005, Hypertension.

[9]  Paul D Allen,et al.  Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. , 2002, The American journal of pathology.

[10]  L. Hawthorn,et al.  Decreased SLIM1 Expression and Increased Gelsolin Expression in Failing Human Hearts Measured by High-Density Oligonucleotide Arrays , 2000, Circulation.

[11]  Ulrich Mansmann,et al.  Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. , 2006, Journal of the American College of Cardiology.

[12]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[13]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[14]  M. Yacoub,et al.  Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. , 2006, European heart journal.

[15]  Jianbo Li,et al.  The gene expression fingerprint of human heart failure , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Shinjo,et al.  Zaprinast, a well‐known cyclic guanosine monophosphate‐specific phosphodiesterase inhibitor, is an agonist for GPR35 , 2006, FEBS letters.